Cardiol Therapeutics (CRDL) Operating Leases: 2021-2022
Historic Operating Leases for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to -$30,739.
- Cardiol Therapeutics' Operating Leases rose 0.62% to -$30,739 in Q3 2022 from the same period last year, while for Sep 2022 it was -$30,739, marking a year-over-year increase of 0.62%. This contributed to the annual value of $58,148 for FY2021, which is N/A change from last year.
- Cardiol Therapeutics' Operating Leases amounted to -$30,739 in Q3 2022, which was down 49.32% from -$20,586 recorded in Q2 2022.
- Cardiol Therapeutics' 5-year Operating Leases high stood at $57,811 for Q4 2021, and its period low was -$30,932 during Q3 2021.
- Its 2-year average for Operating Leases is -$9,438, with a median of -$20,586 in 2022.
- Data for Cardiol Therapeutics' Operating Leases shows a peak YoY rose of 2.52% (in 2022) over the last 5 years.
- Over the past 2 years, Cardiol Therapeutics' Operating Leases (Quarterly) stood at $57,811 in 2021, then climbed by 0.62% to -$30,739 in 2022.
- Its Operating Leases stands at -$30,739 for Q3 2022, versus -$20,586 for Q2 2022 and -$10,247 for Q1 2022.